🇺🇸 FDA

Intelligence · Patent portfolio

Dyne Therapeutics Patents

Full USPTO pharma patent portfolio for Dyne Therapeutics — grant dates, expiration, and drug cross-links.

Patents
82
Expiring ≤24m
3

Quick answer

Dyne Therapeutics has 82 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 3 expire within 24 months — use filters for patent-cliff planning.

Page 1 of 2

  1. US 12428487

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12403203

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12397062

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12370264

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12357703

    Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12329825

    Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12329824

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12325753

    Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy

    Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12319743

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12280122

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12263225

    Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12239716

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12239717

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12203106

    Compositions for increasing polypeptide stability and activity, and related methods

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12173078

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12173079

    Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12168648

    Opioid receptor modulators

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12144867

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12144868

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12128109

    Muscle targeting complexes and formulations for treating dystrophinopathies

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12102687

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12097263

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12018087

    Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12012460

    Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

    Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12005124

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11986537

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11969475

    Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

    Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11931421

    Muscle targeting complexes and formulations for treating myotonic dystrophy

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11932653

    Lycorine derivative, and pharmaceutical composition and use thereof

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11911484

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11866743

    Pharmaceutical formulations, methods for treating chemical warfare agent exposure, and modified biomolecules

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11844843

    Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11839660

    Anti-transferrin receptor antibody and uses thereof

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11833217

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11795233

    Muscle-targeting complex comprising an anti-transferrin receptor antibody linked to an oligonucleotide

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11795234

    Methods of producing muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11787869

    Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11771776

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11759525

    Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

    Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11723762

    LIDAR based 3-D imaging with far-field illumination overlap

    Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11679161

    Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

    Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11672872

    Anti-transferrin receptor antibody and uses thereof

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11648318

    Anti-transferrin receptor (TFR) antibody and uses thereof

    Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11638761

    Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy

    Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11633496

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11633498

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11634452

    Compounds for treating neurodegenerative disorders

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11634396

    Opioid receptor modulators

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Dyne Therapeutics have?

82 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Dyne Therapeutics patents expire?

3 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.